VRDN · Insider Trading
Viridian Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by VRDN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-20 | Jennifer Tousignant | Chief Legal Officer | MIXED | −4,212 | −$204.09K |
| 2026-08-18 | Radhika Tripuraneni | Chief Medical Officer | M | +40,000 | +$528.40K |
| 2026-07-02 | Arlene Morris | Director | A | +32,341 deriv. | — |
| 2026-07-02 | Jeffrey Robert Ajer | Director | A | +32,341 deriv. | — |
| 2026-07-02 | Christopher W. Cain | Director | A | +32,341 deriv. | — |
| 2026-07-02 | Sarah Gheuens | Director | A | +32,341 deriv. | — |
| 2026-07-02 | Tomas Kiselak | Director | A | +32,341 deriv. | — |
| 2026-07-02 | Jennifer K. Moses | Director | A | +32,341 deriv. | — |
| 2026-05-13 | Fairmount Funds Management LLC | Director | Buy | +1,176,470 | +$20.00M |
| 2026-03-09 | Stephen F. Mahoney | President and CEO | F | −7,408 | −$223.65K |
| 2026-03-09 | Seth Harmon | Chief Financial Officer | F | −2,031 | −$61.32K |
| 2026-03-09 | Thomas W. Beetham | Chief Operating Officer | F | −3,048 | −$92.02K |
| 2026-03-09 | Jennifer Tousignant | Chief Legal Officer | F | −1,675 | −$50.57K |
| 2026-03-04 | Seth Harmon | Chief Financial Officer | — | — | — |
| 2026-03-04 | Stephen F. Mahoney | President and CEO | MIXED | +10,730 | −$223.62K |
| 2026-03-04 | Thomas W. Beetham | Chief Operating Officer | MIXED | +6,271 | −$92.01K |
| 2026-03-04 | Jennifer Tousignant | Chief Legal Officer | MIXED | +3,445 | −$50.55K |
| 2026-03-04 | Radhika Tripuraneni | Chief Medical Officer | A | +114,950 deriv. | — |
| 2026-03-04 | Jennifer Tousignant | Chief Legal Officer | — | — | — |
| 2026-03-04 | Seth Harmon | Chief Financial Officer | MIXED | +4,176 | −$61.31K |
| 2026-01-02 | Jennifer Tousignant | Chief Legal Officer | Sell | −2,272 | −$70.80K |
| 2025-10-27 | Fairmount Funds Management LLC | Director | Buy | +454,545 | +$10.00M |
| 2025-07-02 | Jeffrey Robert Ajer | Director | A | +21,000 deriv. | — |
| 2025-07-02 | Arlene Morris | Director | A | +21,000 deriv. | — |
| 2025-07-02 | Jennifer K. Moses | Director | A | +21,000 deriv. | — |
| 2025-07-02 | Christopher W. Cain | Director | A | +21,000 deriv. | — |
| 2025-07-02 | Sarah Gheuens | Director | A | +21,000 deriv. | — |
| 2025-07-02 | Tomas Kiselak | Director | A | +21,000 deriv. | — |
| 2025-06-11 | Fairmount Funds Management LLC | Director | M | +14,100 | +$166.35K |
| 2025-04-09 | Jeffrey Robert Ajer | Director | A | +42,000 deriv. | — |
| 2025-03-12 | Radhika Tripuraneni | Chief Medical Officer | A | +310,700 deriv. | — |
| 2025-03-12 | Christopher W. Cain | Director | A | +42,000 deriv. | — |
| 2025-03-04 | Thomas W. Beetham | Chief Operating Officer | A | +263,450 deriv. | — |
| 2025-03-04 | Seth Harmon | Chief Financial Officer | A | +175,475 deriv. | — |
| 2025-03-04 | Jennifer Tousignant | Chief Legal Officer | A | +144,751 deriv. | — |
| 2025-03-04 | Stephen F. Mahoney | President and CEO | A | +513,993 deriv. | — |
| 2024-09-30 | Thomas W. Beetham | Chief Operating Officer | Buy | +5,000 | +$117.05K |
| 2024-09-30 | Stephen F. Mahoney | President and CEO | Buy | +21,400 | +$499.26K |
| 2024-09-17 | Fairmount Funds Management LLC | Director | Buy | +1,600,000 | +$30.00M |
| 2024-06-28 | Peter Evan Harwin | Director | A | +21,000 deriv. | — |
| 2024-06-28 | Sarah Gheuens | Director | A | +21,000 deriv. | — |
| 2024-06-28 | Arlene Morris | Director | A | +21,000 deriv. | — |
| 2024-06-28 | Jennifer K. Moses | Director | A | +21,000 deriv. | — |
| 2024-06-28 | Tomas Kiselak | Director | A | +21,000 deriv. | — |
| 2024-04-01 | Fairmount Healthcare Fund GP LLC | Director | J | — | — |
| 2024-02-14 | Jennifer Tousignant | Chief Legal Officer | A | +290,000 deriv. | — |
| 2024-02-07 | Thomas Ciulla | Chief Medical Officer | A | +50,000 deriv. | — |
| 2024-01-24 | Fairmount Funds Management LLC | Director | Buy | +476,190 | +$10.00M |
| 2023-11-13 | Seth Harmon | See Remarks | A | +270,000 deriv. | — |
| 2023-11-01 | Stephen F. Mahoney | President and CEO | A | +1,259,400 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Fairmount Funds Management LLC | Director | 5,090,928 | $153.44M |
| Radhika Tripuraneni | Chief Medical Officer | 40,000 | $1.21M |
| Stephen F. Mahoney | President and CEO | 33,349 | $1.01M |
| Thomas W. Beetham | Chief Operating Officer | 13,361 | $402.70K |
| Seth Harmon | Chief Financial Officer | 7,850 | $236.60K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VRDN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.